Melatonin

A hypothesis for Kawasaki disease treatment

Eva Ramos, Paloma Patiño, Russel J Reiter, Emilio Gil-Martín, Francisco López-Muñoz, Alejandro Romero

Research output: Contribution to journalArticle

Abstract

Kawasaki disease (KD) is the most common cause of acquired heart disease with unknown etiology among children in developed countries. Acute inflammation of the vasculature, genetic susceptibility and immunopathogenesis based on a transmittable and infectious origin, are the pathologic events involved in the early inflammatory etiology and progression of this disease. However, the exact causes of KD remain unknown. Current proposed recommendations include three therapy lines; firstly, an initial standard therapy with intravenous immunoglobulin (IVIG) followed by aspirin. Secondly, in cases of high risk of coronary lesions, the adjunctive therapy with corticosteroid is commonly considered. Thirdly, in KD patients refractory to the previous therapies, tumor necrosis factor (TNF-α) antagonists are being used to modulate pro-inflammatory cytokines. In view of this status quo, our starting hypothesis is that the ubiquitous and non-toxic neurohormone melatonin could be of critical importance in developing novel adjuvant therapies against KD, as it occurs with a plethora of other diseases. Considering its pleiotropic properties, particularly its antiinflammatory and immunoregulatory capacities, melatonin should be of great therapeutic interest for helping to control the main pathologic features of KD patients. In addition, this multifunctional indole has a safe pharmacological profile, enhancing the therapeutic activity of several drugs and reducing their possible side effects. Consequently, melatonińs actions to manage KD need to be tested in further clinical studies.

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalMedical Hypotheses
Volume119
DOIs
StatePublished - Oct 1 2018

Fingerprint

Mucocutaneous Lymph Node Syndrome
Melatonin
Therapeutics
Intravenous Immunoglobulins
Genetic Predisposition to Disease
Developed Countries
Aspirin
Neurotransmitter Agents
Disease Progression
Heart Diseases
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Pharmacology
Cytokines
Inflammation
Pharmaceutical Preparations

Keywords

  • Adjuvant therapy
  • Kawasaki disease
  • Melatonin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ramos, E., Patiño, P., Reiter, R. J., Gil-Martín, E., López-Muñoz, F., & Romero, A. (2018). Melatonin: A hypothesis for Kawasaki disease treatment. Medical Hypotheses, 119, 6-10. https://doi.org/10.1016/j.mehy.2018.07.010

Melatonin : A hypothesis for Kawasaki disease treatment. / Ramos, Eva; Patiño, Paloma; Reiter, Russel J; Gil-Martín, Emilio; López-Muñoz, Francisco; Romero, Alejandro.

In: Medical Hypotheses, Vol. 119, 01.10.2018, p. 6-10.

Research output: Contribution to journalArticle

Ramos, E, Patiño, P, Reiter, RJ, Gil-Martín, E, López-Muñoz, F & Romero, A 2018, 'Melatonin: A hypothesis for Kawasaki disease treatment', Medical Hypotheses, vol. 119, pp. 6-10. https://doi.org/10.1016/j.mehy.2018.07.010
Ramos E, Patiño P, Reiter RJ, Gil-Martín E, López-Muñoz F, Romero A. Melatonin: A hypothesis for Kawasaki disease treatment. Medical Hypotheses. 2018 Oct 1;119:6-10. https://doi.org/10.1016/j.mehy.2018.07.010
Ramos, Eva ; Patiño, Paloma ; Reiter, Russel J ; Gil-Martín, Emilio ; López-Muñoz, Francisco ; Romero, Alejandro. / Melatonin : A hypothesis for Kawasaki disease treatment. In: Medical Hypotheses. 2018 ; Vol. 119. pp. 6-10.
@article{6d0d464bdd9a47719c6eba0bc063ffa0,
title = "Melatonin: A hypothesis for Kawasaki disease treatment",
abstract = "Kawasaki disease (KD) is the most common cause of acquired heart disease with unknown etiology among children in developed countries. Acute inflammation of the vasculature, genetic susceptibility and immunopathogenesis based on a transmittable and infectious origin, are the pathologic events involved in the early inflammatory etiology and progression of this disease. However, the exact causes of KD remain unknown. Current proposed recommendations include three therapy lines; firstly, an initial standard therapy with intravenous immunoglobulin (IVIG) followed by aspirin. Secondly, in cases of high risk of coronary lesions, the adjunctive therapy with corticosteroid is commonly considered. Thirdly, in KD patients refractory to the previous therapies, tumor necrosis factor (TNF-α) antagonists are being used to modulate pro-inflammatory cytokines. In view of this status quo, our starting hypothesis is that the ubiquitous and non-toxic neurohormone melatonin could be of critical importance in developing novel adjuvant therapies against KD, as it occurs with a plethora of other diseases. Considering its pleiotropic properties, particularly its antiinflammatory and immunoregulatory capacities, melatonin should be of great therapeutic interest for helping to control the main pathologic features of KD patients. In addition, this multifunctional indole has a safe pharmacological profile, enhancing the therapeutic activity of several drugs and reducing their possible side effects. Consequently, melatonińs actions to manage KD need to be tested in further clinical studies.",
keywords = "Adjuvant therapy, Kawasaki disease, Melatonin",
author = "Eva Ramos and Paloma Pati{\~n}o and Reiter, {Russel J} and Emilio Gil-Mart{\'i}n and Francisco L{\'o}pez-Mu{\~n}oz and Alejandro Romero",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.mehy.2018.07.010",
language = "English (US)",
volume = "119",
pages = "6--10",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Melatonin

T2 - A hypothesis for Kawasaki disease treatment

AU - Ramos, Eva

AU - Patiño, Paloma

AU - Reiter, Russel J

AU - Gil-Martín, Emilio

AU - López-Muñoz, Francisco

AU - Romero, Alejandro

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Kawasaki disease (KD) is the most common cause of acquired heart disease with unknown etiology among children in developed countries. Acute inflammation of the vasculature, genetic susceptibility and immunopathogenesis based on a transmittable and infectious origin, are the pathologic events involved in the early inflammatory etiology and progression of this disease. However, the exact causes of KD remain unknown. Current proposed recommendations include three therapy lines; firstly, an initial standard therapy with intravenous immunoglobulin (IVIG) followed by aspirin. Secondly, in cases of high risk of coronary lesions, the adjunctive therapy with corticosteroid is commonly considered. Thirdly, in KD patients refractory to the previous therapies, tumor necrosis factor (TNF-α) antagonists are being used to modulate pro-inflammatory cytokines. In view of this status quo, our starting hypothesis is that the ubiquitous and non-toxic neurohormone melatonin could be of critical importance in developing novel adjuvant therapies against KD, as it occurs with a plethora of other diseases. Considering its pleiotropic properties, particularly its antiinflammatory and immunoregulatory capacities, melatonin should be of great therapeutic interest for helping to control the main pathologic features of KD patients. In addition, this multifunctional indole has a safe pharmacological profile, enhancing the therapeutic activity of several drugs and reducing their possible side effects. Consequently, melatonińs actions to manage KD need to be tested in further clinical studies.

AB - Kawasaki disease (KD) is the most common cause of acquired heart disease with unknown etiology among children in developed countries. Acute inflammation of the vasculature, genetic susceptibility and immunopathogenesis based on a transmittable and infectious origin, are the pathologic events involved in the early inflammatory etiology and progression of this disease. However, the exact causes of KD remain unknown. Current proposed recommendations include three therapy lines; firstly, an initial standard therapy with intravenous immunoglobulin (IVIG) followed by aspirin. Secondly, in cases of high risk of coronary lesions, the adjunctive therapy with corticosteroid is commonly considered. Thirdly, in KD patients refractory to the previous therapies, tumor necrosis factor (TNF-α) antagonists are being used to modulate pro-inflammatory cytokines. In view of this status quo, our starting hypothesis is that the ubiquitous and non-toxic neurohormone melatonin could be of critical importance in developing novel adjuvant therapies against KD, as it occurs with a plethora of other diseases. Considering its pleiotropic properties, particularly its antiinflammatory and immunoregulatory capacities, melatonin should be of great therapeutic interest for helping to control the main pathologic features of KD patients. In addition, this multifunctional indole has a safe pharmacological profile, enhancing the therapeutic activity of several drugs and reducing their possible side effects. Consequently, melatonińs actions to manage KD need to be tested in further clinical studies.

KW - Adjuvant therapy

KW - Kawasaki disease

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=85049801905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049801905&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2018.07.010

DO - 10.1016/j.mehy.2018.07.010

M3 - Article

VL - 119

SP - 6

EP - 10

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

ER -